1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsPage states 'Requests for Proposals will be announced in the coming months' — no application open yet as of the announcement date (Feb 24, 2026). Stored deadline of 2026-10-05 may be correct once RFP opens.
2026 LCRF | AstraZeneca Research Award on Strategies Using Patient Advocacy to Improve Outcomes in Small Cell Lung Cancer is sponsored by Lung Cancer Research Foundation (LCRF) and AstraZeneca. Supports initiatives using patient advocacy to enhance outcomes for small cell lung cancer patients.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
LCRF + AstraZeneca launch SCLC grant - Lung Cancer Research Foundation Enter your search term above.
LCRF + AstraZeneca launch SCLC grant Two new lung cancer research grants aim to accelerate discoveries and enhance outcomes in Small Cell Lung Cancer treatment NEW YORK, NY (February 24, 2026) – The Lung Cancer Research Foundation (LCRF) announces a new research collaboration with AstraZeneca aimed at driving progress in small cell lung cancer (SCLC) with two grant awards, 2026 LCRF | AstraZeneca Research Award on Strategies Towards Improving the Treatment of Small Cell Lung Cancer and 2026 LCRF | AstraZeneca Research Award on Strategies Using Patient Advocacy to Improve Outcomes in Small Cell Lung Cancer .
Lung cancer is responsible for more deaths worldwide than any other cancer, accounting for an estimated 124,990 deaths annually in the United States alone. 1 Small cell lung cancer (SCLC) represents 13-15% of lung cancer cases with a 5-year survival rate of less than 7%. 1 , 2 It is characterized by rapid proliferation and early metastatic spread.
Only a small fraction of patients present with earlier stage disease that is amenable to potentially curative treatment with combined modality therapy. Lung cancer screening initiatives have resulted in a 20% reduction in mortality for non-small cell lung cancer (NSCLC), but have not had the same benefit for SCLC patients, probably because of the aggressive nature of the disease.
While there have been significant advancements in the treatment of NSCLC, there has been very little movement for SCLC, both in the understanding of the biology of SCLC and treatment. Recently, there has been a characterization of SCLC subtypes that may have distinct therapeutic vulnerabilities. Untreated SCLC is initially sensitive to DNA-damaging agents with impressive clinical response.
Unfortunately, treatment resistance is inevitable and second-line therapy is less effective. The introduction of immunotherapy in first-line treatment has resulted in modest improvements in the treatment of extensive SCLC and a significant improvement in overall survival for patients with limited stage disease. 3 , 4 , 5 There have been attempts at identifying targets for more directed treatment.
DLL3, an inhibitory Notch pathway ligand, represents a potential therapeutic target in SCLC because it is frequently expressed on the surface of SCLC tumor cells. Discovering both biomarkers that predict treatment benefit and novel therapeutic targets represents a great area of need to make substantial progress in SCLC.
Considering that scientists are just scratching the surface when it comes to understanding the biology of SCLC and given that most therapeutic options available to date are usually not curative, there is a need for novel approaches to treat SCLC and improve outcomes for patients with the ultimate intention of cure. Understanding the biology of a disease and developing treatments is often supported and amplified by patient advocacy.
Diligent patient advocacy has been responsible for advancements in a number of diseases, including HIV/AIDS, breast cancer, and Alzheimer’s disease. Despite it being the leading cause of cancer deaths in the US, lung cancer has the smallest advocacy score of any major disease. 6 One of the greatest barriers to developing effective advocacy initiatives has been the stigma associated with lung cancer.
Given the limited research and clinical progress in SCLC, it is unsurprising that advocacy for this patient population represents a critical and urgent unmet need. The 2026 LCRF | AstraZeneca Research Award on Strategies Towards Improving the Treatment of Small Cell Lung Cancer is a $500,000, three-year award that will focus on furthering the development of novel strategies towards improving the treatment of SCLC.
Work supported through this mechanism will address important areas of need across the entire care continuum and have the immediate potential to increase survivorship. It is expected that correlative translational research will be proposed that will enhance the understanding of SCLC.
The 2026 LCRF | AstraZeneca Research Award on Strategies Using Patient Advocacy to Improve Outcomes in Small Cell Lung Cancer is a $250,000, two-year award that will focus on furthering the development of strategies towards improving the outcomes of SCLC patients through patient advocacy.
Work supported through this mechanism will address important areas of need across the entire care continuum and have the immediate potential to increase research efforts, quality of life and survivorship.
“A deeper understanding of small cell lung cancer biology is essential to advancing more precise and effective therapies—and ultimately improving care and outcomes for people living with this challenging disease,” said Nabil Chehab, US Medical Head, Lung Cancer, AstraZeneca.
“We’re proud to partner with the Lung Cancer Research Foundation to accelerate research and to engage patients and their support networks, moving small cell lung cancer science forward. ” “LCRF’s research program is centered on delivering solutions for lung cancer patients.
Including patients in research ensures that their most pressing needs are met, both near-term and long-term,” says Dr. Antoinette Wozniak, Chief Scientific Officer for LCRF. “Patients are our partners in discovery and their voices help define research priorities and drive meaningful outcomes. Collaboration is the key to addressing unmet needs for the community.
I know that AstraZeneca shares our commitment to provide hope through impactful research. ” Requests for Proposals will be announced in the coming months. To be notified when submission will be accepted, please visit LCRF.
org/RFPlist . About the Lung Cancer Research Foundation (LCRF) Lung Cancer Research Foundation (LCRF) Sheila Sullivan, Senior Director, Marketing & Communications American Cancer Society. Cancer Facts & Figures 2026 , Atlanta: American Cancer Society; 2026.
Megyesfalvi Z, Gay CM, Popper H, et al. CA Cancer J Clin. 2023; 73(6): 620-652.
Horn L, Mansfield AS, Szczęsna A, et al. N Engl J Med. 2018; 379(23): 2220-2229.
Paz-Ares L, Dvorkin M, Chen Y, et al. Lancet. 2019; 394(10212): 1929-1939.
Cheng Y, Spigel D, Cho BC, et al. N Engl J Med. 2024; 391(14): 1313-1324.
Best RK. Oxford University Press. 2019; 10.
1093/oso/9780190918408. 001. 0001.
Posted in Announcements , Research , SCLC Tagged News , Research , SCLC
According to the current listing, eligibility includes: Researchers and organizations focused on developing patient advocacy strategies to improve outcomes in Small Cell Lung Cancer. Confirm the full requirements in the official notice before applying.
The current listing shows $250,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for 2026 LCRF | AstraZeneca Research Award on Strategies Using Patient Advocacy to Improve Outcomes in Small Cell Lung Cancer are due October 5, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
2026 LCRF | AstraZeneca Research Award on Strategies Using Patient Advocacy to Improve Outcomes in Small Cell Lung Cancer is funded by Lung Cancer Research Foundation (LCRF) and AstraZeneca. Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articleCDC-RFA-DP-27-0023 puts the National Breast and Cervical Cancer Early Detection Program, the National Comprehensive Cancer Control Program, and the National Program of Cancer Registries into a single competition closing February 5, 2027. Three statutorily separate eligibility pools, one application deadline, and an award count that maps onto the incumbent footprint. Here is how to read that.
Read articleCDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read article